Core Insights - ArcBest Corp reported mixed fourth-quarter 2025 results with revenue of $972.7 million, down from $1.0 billion a year earlier, and adjusted earnings of 36 cents per share, missing the analyst estimate of 41 cents [1] - The results included a $9.1 million after-tax, noncash impairment charge [1] Group 1: Financial Performance - Revenue for the fourth quarter was $972.7 million, exceeding expectations of $966.361 million [1] - Adjusted earnings per share were 36 cents, which fell short of the analyst estimate of 41 cents [1] - The company faced a $9.1 million after-tax, noncash impairment charge impacting overall financial results [1] Group 2: Management Commentary - The President and CEO highlighted 2025 as a year of strong execution and meaningful progress despite a challenging freight environment [2] - The company achieved growth in LTL shipments and tonnage, restored profitability in Asset-Light, and reached record productivity levels [2] Group 3: Stock Performance and Analyst Ratings - ArcBest shares increased by 6.4% to trade at $96.01 following the earnings announcement [2] - Analysts have adjusted their price targets, with Jefferies raising it from $95 to $110 while maintaining a Buy rating [4] - JP Morgan maintained a Neutral rating and raised the price target from $76 to $81, and Wells Fargo maintained an Equal-Weight rating with a price target increase from $74 to $85 [4]

Group 1 - Morgan Stanley analyst Meta Marshall raised the price target on Coherent (COHR) to $190 from $180 while maintaining an Equal Weight rating on the shares [1] - Coherent has outperformed Lumentum (LITE) year-to-date, indicating a positive performance trend [1] - The firm expresses a more positive outlook on COHR compared to LITE ahead of the earnings report, as expectations for COHR are lower [1]

Group 1 - Citizens JMP analyst Jonathan Wolleben lowered the price target on Altimmune (ALT) to $14 from $15 while maintaining an Outperform rating on the shares [1] - The firm anticipates the oral late-breaking presentation of pemvidutide's Phase 2b data at the Liver Meeting, with 48-week data expected to be released this quarter [1]